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A B S T R A C T
Introduction: Thromboembolism (TE) is a common and serious toxicity of acute lymphoblastic leukemia (ALL)
treatment, but studies of genetic predisposition have been underpowered with conflicting results. We tested
whether TE in ALL and TE in the general adult population have a shared genetic etiology.
Materials and methods: We prospectively registered TE events and collected germline DNA in patients
1.0–45.9 years in the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 study (7/
2008–7/2016). Based on summary statistics from two large genome-wide association studies (GWAS) on venous
TE in adults (the International Network of VENous Thromboembolism Clinical Research Networks (INVENT)
consortium and the UK Biobank), we performed polygenic risk score (PRS) analysis on TE development in the
NOPHO cohort, progressively expanding the PRS by increasing the p-value threshold of single nucleotide
polymorphism (SNP) inclusion.
Results and conclusion: Eighty-nine of 1252 patients with ALL developed TE, 2.5 year cumulative incidence 7.2%.
PRS of genome-wide significant SNPs from the INVENT and UK Biobank data were not significantly associated
with TE, HR 1.16 (p 0.14) and 1.02 (p 0.86), respectively. Expanding PRS by increasing p-value threshold did not
reveal polygenic overlap. However, subgroup analysis of adolescents 10.0–17.9 years (n = 231), revealed sig-
nificant polygenic overlap with the INVENT GWAS. The best fit PRS, including 16,144 SNPs, was associated with
TE with HR 1.76 (95% CI 1.23–2.52, empirical p-value 0.02). Our results support an underlying genetic pre-
disposition for TE in adolescents with ALL and should be explored further in future TE risk prediction models.
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Patients with acute lymphoblastic leukemia (ALL) are at increased
risk of thromboembolism (TE) due primarily to the cancer, the che-
motherapy treatment (not least asparaginase), and the presence of
central venous lines. A meta-analysis from 2006 found a 5.2% incidence
of TE in children with ALL, and several studies have found that this risk
increases in adolescents> 10 years and in adults [1–3]. To study the
genetics of TE, large sample sizes are needed [4], which is challenging
in the setting of patients with ALL. A genome wide association study
(GWAS) on TE in children with ALL did not reveal genome-wide sig-
nificant hits, but was also underpowered [5]. In contrast, there exist
large GWAS on venous TE in the general adult population, for example
the 2015 GWAS from the International Network of VENous Throm-
boembolism Clinical Research Networks (INVENT) and the 2017 UK
Biobank GWAS, which have found several single nucleotide poly-
morphisms (SNPs) robustly associated with venous TE from the F5,
FGG, F11, ABO, F2, PROCR TSPAN15, SLC44A2, and ZFPM2 genes.
Attempts to extrapolate from the genetics of TE in the general po-
pulation to the genetics of TE in patients with ALL have been many and
the results diverging, making it difficult to draw sound conclusions.
However, by creating polygenic risk scores (PRS) based on large GWAS
on TE in the general population, we can summarize the effects of
multiple SNPs to identify individuals at increased risk. Because PRS, in
contrast to GWAS, are not challenged by the need for correction for
multiple testing, the power to detect association is higher than when
testing the SNPs individually. The PRS also allow the inclusion of SNPs
that do not reach genome-wide significance, but may still play an ad-
ditive role in a complex phenotype. Importantly, the PRS also allow us
to investigate the extent of common genetic etiology between venous
TE in the general adult population and TE in patients with ALL, which is
currently unknown. Identification of overlapping etiology can subse-
quently be used to identify SNPs to be incorporated in prediction
models to identify patients eligible for thromboprophylaxis.
We aimed to test the hypothesis that TE in ALL and TE in the general
adult population have a shared genetic etiology. Secondly, we explored
if this would be different for patients with ALL in different age groups.
Based on large GWAS on TE in the general adult population, we per-
formed PRS analyses on individual-level data in the Nordic Society of
Pediatric Hematology and Oncology (NOPHO) ALL2008 cohort. We
also investigated the effect of the 37-SNP venous TE-associated PRS
from the 2019 INVENT GWAS [6] on risk of TE in ALL.
2. Materials and methods
2.1. Patient population
From 7/2008 to 7/2016, patients diagnosed with ALL and treated
according to the NOPHO ALL2008 study were invited to participate in
genetic add-on studies. The NOPHO ALL2008 study, which was a po-
pulation based treatment and research protocol for ALL patients
1.0–45.9 years old in Denmark, Estonia, Finland, Iceland, Lithuania,
Norway, and Sweden, has been described in detail elsewhere [1,7–10],
and was approved by the national authorities and the relevant national
or regional ethical committees in each participating country. Partici-
pation in the genetic add-on study required additional informed consent
and was approved by the ethical committees in the participating
countries. The study was conducted in accordance with the Declaration
of Helsinki. Data on patient demographics, ALL characteristics, and
treatment were collected from the NOPHO registry on October 10th
2017, and patients with ALL predisposition syndromes, such as ataxia
telangiectasia or Downs syndrome, patients with bilineage or ambig-
uous phenotype, and patients not following the treatment protocol were
excluded (Fig. 1). Samples on 1812 individuals were sent to genotyping,
and after clinical and genetic quality control, 1252 patients were in-
cluded in the genetic study, which has been described previously
(Fig. 1) [11].
2.2. TE events
TE events during ALL treatment were registered as part of the
mandatory prospective toxicity registration in NOPHO ALL2008 [9]. TE
was defined as first-time symptomatic arterial or venous TE verified by
imaging or asymptomatic arterial or venous TE diagnosed by imaging
due to non-TE related symptoms and requiring anticoagulation treat-
ment. The date of TE was defined as the date of diagnostic image
analysis or the date of death if diagnosed at autopsy.
2.3. Genetic data
SNP profiling of post-remission DNA in the NOPHO cohort was done
using the Omni 2.5exome-8-BeadChip arrays (Illumina, San Diego, CA,
USA). The imputation procedure has been described previously [11].
Standard quality control procedures were performed according to pre-
viously published criteria [12,13], excluding individuals with: (i) sex
mismatch; (ii)> 2% missing genotyped SNPs; (iii) excess hetero-
zygosity; or (iv) high relatedness/duplicate samples. SNPs were ex-
cluded based on: (i)> 2% missing genotyped individuals; (ii) minor
allele frequency (MAF) < 0.01; or (iii) Hardy-Weinberg-equilibrium
(p < 0.00001). Genetic ancestry was determined according to identity
by state clustering analysis, removing individuals> 15 standard de-
viations away from the HapMap defined CEU (Northern European)
centroid mean. The threshold for certainty of the SNP imputation was
set at 0.7.
We obtained summary statistics from two large-scale genomic stu-
dies; the 2015 INVENT GWAS [14], comprising 7507 venous TE cases
and 52,632 controls, and the 2017 UK Biobank GWAS [15], including
3920 venous TE cases and 116,868 controls, all of European ancestry.
Details on the inclusion criteria and phenotype characteristics are de-
scribed in the original publications [14,15].
2.4. Statistical analyses
The PRS were constructed from the summary statistics using the
PRSice software [16], and the PRS weights were standardized to a Z-
score with a mean of 0 and a standard deviation (SD) of 1. We first
considered only genome-wide significant SNPs (p < 5 ∗ 10−8), and
then gradually relaxed the p-value threshold to include more SNPs in
the PRS to capture polygenicity. Power calculations performed using
the Avengeme package in R [17] showed that for an overall alpha of
0.05 (supplementary material) [18], we have power > 80% when
including up to 17,300 and 8300 SNPs from the 2015 INVENT and the
2017 UK Biobank summary statistics, respectively. The PRS plots were
stopped at p-value threshold 0.03 (including 34–22,700 and 6–27,000
SNPs from the 2015 INVENT and 2017 UK Biobank summary statistics,
respectively). The PRSice software automatically performs linkage
disequilibrium (LD)-clumping. Due to the strong effect-sizes of a few
well-known SNPs, we repeated the analyses excluding the LD-regions
around F5 rs6025, F11 rs2036914, FGG rs2066865, and ABO
rs8176719 as a sensitivity analysis (supplementary material).
Based on the 2019 INVENT GWAS meta-analysis, which also in-
cluded the UK Biobank data, a 37 SNP PRS was proposed for venous TE
in adults including 34 genome-wide significant variants and 3 pre-
viously identified variants with p-value < 5.6 × 10−3 without
reaching genome-wide significance [6]. Of the 37 SNPs from the 2019
INVENT PRS [6], we had missing data on 3 SNPs (F9 rs6048 and F8
rs143478537 on the X chromosome, and rs191945075 downstream of
F2 with MAF 0.01), leaving 34 SNPs in the PRS. The PRS34 was cal-
culated as the sum of the effect alleles per patient, each multiplied by
their reported effect size, and standardized to a z-score.
The PRS were analyzed using a Cox regression model of time to TE
event. Patients were censored at end of ALL treatment (n = 977), loss
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to follow-up (n = 4), date of hematopoietic cell transplantation
(n = 61), date of data collection (10.10.2017) (n = 138) or date of
competing event (death, relapse or second primary malignancy)
(n = 72), whichever came first. In all Cox models we controlled for age
as a categorical variable (1.0–9.9 years, 10.0–17.9 years, or
18.0–45.9 years) based on our previous NOPHO study [11], sex, and the
first two genetic principal components. We used a stratification ap-
proach to the subgroup analysis by age group since our study is un-
derpowered for modeling an age-PRS interaction. PRS HRs are reported
for 1 SD from the mean. The null hypothesis was that TE in ALL and TE
in adults in the general population do not have a shared genetic
etiology. Since we looked at a wide range of PRS, we used 10,000
permutations to calculate empirical p-values; thus properly controlling
the type 1 error rate for calculating PRS at a large number of evenly
spaced p-value thresholds.
A drop-out analysis was performed comparing patients in the ge-
netic cohort with patients not included in the genetic cohort, but
meeting the same clinical criteria without excluding non-European
ancestry. All statistical analyses were performed using R computing
software, version 3.4.3.
3. Results
There were 658 patients treated according to the NOPHO ALL2008
study that met the clinical inclusion criteria of the genetic cohort, but
were not included due to lack of consent, failed genetic quality control
or non-European ancestry, while 1252 patients were included. Drop-out
analysis (see Supplementary Table S1) revealed more adults and pa-
tients with T-cell ALL among the non-included patients. There was no
significant difference in number of TE events (p 0.11). Eighty-nine of
1252 patients with ALL in the genetic cohort developed TE (2.5 year
cumulative incidence 7.2%, 95% confidence interval (CI) 5.7–8.6) at a
median 12.7 weeks (50% range: 7.4–18.1 weeks) from diagnosis. There
were 50 (56.2%) deep vein thromboses, including one combined ar-
terial and venous event in the portal hepatic system, 25 (28.1%) cere-
bral sinovenous thromboses (CSVT), and 14 (15.7%) pulmonary em-
bolisms. Data on patient characteristics and cumulative incidences of
TE are displayed in Table 1.
PRS of genome-wide significant SNPs from the 2015 INVENT GWAS
[14], including 34 SNPS, and from the 2017 UK Biobank GWAS [15],
including 6 SNPs, were not associated with increased risk of TE in the
NOPHO cohort; HR 1.16 (95% CI 0.95–1.42, p 0.14) and 1.02 (95% CI
0.83–1.26, p 0.86), respectively.
A stepwise increase in the significance threshold to include more
SNPs from the 2015 INVENT and the 2017 UK Biobank GWAS did not
reveal evidence of polygenic overlap with TE in patients with ALL
(Fig. 2).
Subdividing the population into patients< 10 years (n = 894) or
≥10 years (n = 358) did not change the result (Supplementary Fig.
S1). However, when separating adolescents 10.0–17.9 years (n = 231)
from adults ≥18 years (n = 127), we saw polygenic overlap between
the 2015 INVENT GWAS and TE in adolescents 10.0–17.9 years, al-
though the numbers were small (Fig. 3). The best fit PRS included
16,144 SNPs from the 2015 INVENT GWAS (p-value threshold 0.01925)
demonstrating a HR 1.76 (95% CI 1.23–2.52, empirical p-value 0.02).
Five of 11 adolescents in the top 5% of PRS16144 and 10 of 46 adoles-
cents in the top 20% of PRS16144 developed TE (cumulative incidence
45.5%, 95% CI 14.0–76.8, and 21.8%, 95% CI 9.7–33.1, respectively).
In comparison, the cumulative incidence of TE in the adolescent po-
pulation in the middle range of PRS16144 was 13.9% (95% CI 7.5–20.3)
(Table 2). Excluding the LD-regions around the well described func-
tional SNPs from the F5, ABO, FGG and F11 locus did not substantially
change the results (Supplementary Fig. S2).
Neither an association between the 2019 INVENT PRS34 and TE
development in patients with ALL (HR 1.12, 95% CI 0.91–1.38, p 0.28)
nor in subgroup analysis of patients 10.0–17.9 years old (Table 2) was
found.
4. Discussion
In this large cohort of patients with ALL and TE, we found neither an
association for PRS including only genome-wide significant SNPs from
the 2015 INVENT or the 2017 UK Biobank GWAS with TE in ALL nor an
association for the proposed 2019 INVENT PRS34 [6]. A lot of focus in
the field of PRS is on identifying individuals at high risk for use in
precision medicine. However, PRS can also be useful in helping us
understand the shared genetic etiology between diseases, especially in
situations where one of the patient populations is rare. We did not see
evidence of overlapping polygenic etiology between the adult summary
statistics and TE in the full NOPHO-cohort. However, there was
1812 children and adults with ALL treated 
according to NOPHO ALL2008, 2008-2016
28 non-consenters
143 excluded for non-European ancestry
1252 paents in the genec study cohort
80 excluded for clinical criteria:
- Other protocol/treatment abroad (8)
- ALL predisposion syndromes (44)
- Ambiguous phenotype/bilineage (19)
- Missing clinical data (7)
- Age >45 years old (2)
309 failed genec quality control
Fig. 1. Flowchart.
Reprinted from K.B. Jarvis et al., Candidate single nucleotide polymorphisms and thromboembolism in acute lymphoblastic leukemia — a NOPHO ALL2008 study,
Thromb. Res. 184 (2019) 92–98, with permission from Elsevier.
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significant polygenic overlap between the INVENT summary statistics
and TE in patients 10.0–17.9 years with ALL in subgroup analysis.
In the subgroup analysis by age group the absolute numbers were
small. In addition, the polygenic overlap curve between the INVENT
summary statistics and TE in adolescents with ALL was broad with no
clear peak—making it difficult to ascertain the ideal number of SNPs to
include in the PRS. Using permutation analysis to correct for the mul-
tiple testing the top PRS had p-value 0.02. This means that given that
there is no association, there is still a 2% chance of finding a result like
ours or more extreme. Thus, it is possible that it is a chance finding, but
we believe it is interesting enough to merit further investigation. We
know that adolescents are at increased risk of TE compared to chil-
dren< 10 years [1]. In our previous candidate SNP study, we also
found the strongest effect of the significant SNPs in adolescents [11].
Adolescents go through changes in hormonal profile and it is possible
that this affects the genetic risk. It is more surprising that we do not find
evidence of genetic overlap in adults. However, we know that in gen-
eral TE occurs more frequently in adults as part of natural aging, while
children and adolescents are physiologically protected. It is reasonable
that genetics might play a stronger role in the high risk situation of
cancer and chemotherapy in adolescents who do not have as many
additional exogenic risk factors as adults. It is also possible that some
adults were protected by anticoagulation prophylaxis, which is more
commonly used in adults; however, the previous clinical study on TE in
the NOPHO ALL2008 cohort found that about 17% of patients
≥17 years received anticoagulation prophylaxis, but the incidence of
TE was similar as for those without prophylaxis [1].
We found no effect of the top SNPs associated with venous TE in the
general adult population, despite high power. Many of these top var-
iants have been explored individually in previous studies of TE in pa-
tients with ALL, but the results have been conflicting. An example is the
role of blood group O (rs8176719) and the factor V Leiden mutation
(rs6025), both of which are among the strongest genome-wide sig-
nificant variants in adult studies. We recently found no effect of
rs8176719 and rs6025 on risk of TE in this population of patients with
ALL [11].
We did not see any evidence of polygenic overlap with the 2017 UK
Biobank GWAS, as the HRs were stable around 1. This may be related to
slightly inferior power of the UK Biobank GWAS compared to the 2015
INVENT GWAS due to fewer cases. In addition, the 2015 INVENT meta-
Table 1
Patient characteristics and 2.5 year cumulative incidence of TE.




Cumulative incidence of TE 95% CI
Age 1.0–9.9 years 860 (73.9) 34 (38.2) 3.8% 2.6–5.1
10.0–17.9 years 197 (17.0) 34 (38.2) 14.8% 10.2–19.5
18.0–45.9 years 106 (9.1) 21 (23.6) 16.7% 10.2–23.3
Sex Male 644 (55.4) 54 (60.7) 7.8% 5.8–9.8
Female 519 (44.6) 35 (39.3) 6.3% 4.3–8.4
Phenotype Precursor-B cell 1008 (86.7) 65 (73.0) 6.1% 4.7–7.5





























PRS of adult summary statistics on TE in NOPHO Fig. 2. Polygenic overlap with TE in NOPHO.
The plots show the polygenic overlap between the 2015
INVENT GWAS above and the 2017 UK Biobank GWAS
below and TE in patients with ALL in NOPHO. The HRs of
the PRS are on the y-axis and the p-value threshold for
SNP inclusion in the PRS on the x-axis. The upper and
lower limits of the 95% confidence intervals are given
with the dark red and red dotted lines respectively. (For
interpretation of the references to color in this figure le-
gend, the reader is referred to the web version of this
article.)
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analysis was based on mostly case-control studies with venous TE cases
confirmed through image-analysis, while the UK Biobank data were
based on electronic health records and medical code-based phenotypes,
which may result in a less precise phenotype [15]. Though the 2015
INVENT and 2017 UK Biobank GWAS included both deep vein throm-
boses and pulmonary embolisms, they did not include CSVT, which
made up 28% of the NOPHO TE events. We did not exclude the CSVT
cases as they are also venous thromboembolic events and because it
would reduce the power; however, if the CSVT cases have different
genetic risk factors this may have attenuated the polygenic overlap.
Strengths of this study are that we have a large cohort of patients
with the same diagnosis and uniform treatment with prospective toxi-
city registration and high registration compliance [9]. The events occur
early during ALL treatment and there is hardly loss of patients to follow-
up before end of treatment. The patients censored while still on treat-
ment at date of data collection had all completed at least the first year
of treatment and were thus past the period of highest risk of TE. Ad-
ditionally, we had excellent power to detect overlapping polygenetic
etiology between TE in the general adult population and TE in patients
with ALL for a limited number of SNPs. However, due to limited
numbers we did not have power to test all PRS with p-value thresholds
up to 1.0, nor a formal test of a PRS-age interaction. A limitation to the
study is a delay in consent to participation in the genetic add-on study
in some cases; thus there may have been early deaths that were not
included. This might explain why drop-out analysis revealed more
adults and patients with T-cell ALL among those not included. How-


























































































UK Biobank (patients 18.0−45.9 years)
PRS from adult summary statistics on TE in NOPHO
Fig. 3. Polygenic overlap with TE in NOPHO per age group.
The plots show the polygenic overlap between the 2015 INVENT GWAS on the left and the 2017 UK Biobank GWAS on the right and TE in patients with ALL in
NOPHO per age group. The HRs of the PRS are on the y-axis and the p-value threshold for SNP inclusion in the PRS on the x-axis. The upper and lower limits of the
95% confidence intervals are given with the dark red and red dotted lines respectively. (For interpretation of the references to color in this figure legend, the reader is
referred to the web version of this article.)
Table 2
Impact of PRS18964 and PRS34 on risk of TE among patients 10.0–17.9 years.
PRS High PRS Reference
group
Patients 10.0–17.9 years
HR 95% CI p-Value
PRS16144 Top 20% Remaining 80% 1.83 0.87–3.85 0.11
Top 10% Remaining 90% 1.84 0.87–4.53 0.18
Top 5% Remaining 95% 4.40 1.64–11.8 0.003
2019 INVENT
PRS34
Top 20% Remaining 80% 0.67 0.26–1.72 0.40
Top 10% Remaining 90% 0.54 0.13–2.29 0.41
Top 5% Remaining 95% 0.58 0.08–4.27 0.60
HRs are calculated comparing those with high PRS with the remained of the
population in a cox regression model controlling for sex and the first two ge-
netic principal components.
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observation time and due to our prospective study design, this should
not cause a large bias to our study.
5. Conclusion
Part of the unexplained variation in TE development in patients
with ALL may be due to genetics. However, this exploratory analysis
shows that the main genetic factors associated with TE in the general
adult population are not important in the setting of TE in patients with
ALL. Patients with ALL are a unique group with clear clinical risk fac-
tors for TE, and the usefulness of genetic studies on TE in the general
adult population is limited when it comes to understanding the etiology
of TE in patients with ALL. However, we found evidence of polygenic
overlap in subgroup analysis of adolescents aged 10.0–17.9 years with
ALL, and we believe the genetics of TE in this group should be further
explored in future risk prediction models for identification of those who
might benefit from thromboprophylaxis.
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